Navigation Links
Thomson Scientific Announces BONDplus for Biological Researchers
Date:9/10/2007

Life Science Platform Delivers Real Time, Comprehensive and Seamless Public and Proprietary Biological Sequence, Interaction and Patent Information

PHILADELPHIA, Sept. 10 /PRNewswire-FirstCall/ -- Thomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, announced today the release of BONDplus, an integrated, web-based data platform to address the information and analytic needs of biological researchers.

Compiled from 15 assembled resources including GenBank, RefSeq, Entrez Gene and UniProtKB/Swiss-Prot, BONDplus allows researchers to move beyond the genome and leverage publicly available biological sequence data, BINDplus biomolecular interaction data as well as GENESEQ, a value added database of patented biological sequences. The platform allows novel insights into biological research including target-based discovery and rational drug design.

"Today's life science data management faces considerable hurdles due to years of fragmented and non-standardized production of biological data," said Jon Brett-Harris, executive vice president of pharmaceutical and chemical markets at Thomson Scientific. "Since solutions are frequently focused on one data type or in a niche area, an integrated platform can provide a distinct competitive advantage, allowing scientists not only to access public domain data, but also to integrate their own proprietary data and value-added Thomson Scientific data in a consistent and user-friendly format."

BONDplus provides an intuitive and value-added resource for any researcher by uniting the genomic, proteomic and metabolomic research communities around one comprehensive platform. The subscription service provides information from over 15 assembled resources including BINDplus and GENESEQ in addition to pre- computed data sets with BLAST functionality, visualization tools and over 80 million in public domain sequences.

A leading provider of life science research information, Thomson serves primary, secondary and tertiary data types, ranging from proteins and small molecules to gene and protein expression and more complex data types such as toxicology/efficacy data, biomarker, interaction and pathway information.

For more information on BONDplus, please visit: http://scientific.thomson.com/bondplus/

About The Thomson Corporation

The Thomson Corporation (http://www.thomson.com) is a global leader in providing essential electronic workflow solutions to business and professional customers. With operational headquarters in Stamford, Conn., Thomson provides value-added information, software tools and applications to professionals in the fields of law, tax, accounting, financial services, scientific research and healthcare. The Corporation's common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC).

Thomson Scientific is a business of The Thomson Corporation. Its information solutions assist professionals at every stage of research and development-from discovery to analysis to product development and distribution. Thomson Scientific information solutions can be found at scientific.thomson.com.


'/>"/>
SOURCE Thomson Scientific
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Scientific markers of aging described
2. A Settlement Over Stem Cell Controversy Through Scientific Research
3. A Scientific Explanation For Out Of Body Experience
4. PUFA Good For Heart: Gets The Scientific Seal
5. Forensic Phonetics – Scientific Solution for Legal Problem
6. Old Indian Advice Has A Scientific Backing Now!
7. India To Highlight Its Scientific Achievements
8. Thumbs up in weight loss for vegetarian diets: scientific review
9. Scientific Research in a War Zone
10. Unscientific Depression Drugs aplenty in Health Stores
11. No Scientific Evidence to Support Drug Safety Recommendations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... , ... Are You Concerned About Mold In Your Home or Workplace? ... Companies in VA, MD and DC, recently completed its application for the new District ... in the district of Columbia is a good thing stated John Taylor, Owner of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, ... of its 60-day free trial program for all of the company’s desktop riser ... a truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... Through an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to ... “Early on I learned that medicine is about more than making diagnoses and prescribing ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. ... months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) ... a significantly better safety and tolerability profile of ropeginterferon alfa-2b ... from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV to ... PharmaEssentia intends to present this data to the FDA ...
(Date:12/4/2016)... 3, 2016 Sickle cell disease (SCD) is ... blood cells that get stuck in veins and block ... failure, and complications leading to death. Each year, approximately ... and most of them lack access to comprehensive care ... long-term therapy for SCD, a pill called hydroxyurea approved ...
Breaking Medicine Technology: